FLT3 and acute myeloid leukemia: Based on these observations, the 2017 European LeukemiaNet (ELN) recommendations commented that NPM1‐mutated AML patients can be categorized into either intermediate or favorable risk groups depending on their FLT3‐ITD status and the AR [13].